CPX-351
CPX-351 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Acute Myeloid Leukemia、TP53。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
16 项
全球在招研究
1 项
已进入 III/IV 期
11 个
开展国家和地区
暂未检索到
中国境内设点
药品与企业信息
研发企业
- Masonic Cancer Center, University of Minnesota
- M.D. Anderson Cancer Center
- Nantes University Hospital
- National Cancer Institute (NCI)
- Acute Leukemia French Association
- Princess Maxima Center for Pediatric Oncology
- Georgetown University
- Children's Oncology Group
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、法国、加拿大、Puerto Rico、奥地利、丹麦、德国、意大利、荷兰、西班牙、澳大利亚
正在招募患者的 CPX-351 研究
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
II 期招募中美国NCT04493164Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)
I 期招募中法国NCT05749276MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
II 期招募中美国加拿大Puerto RicoNCT05564390Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
不适用招募中法国NCT04777916Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
II 期招募中美国加拿大Puerto RicoNCT05554406Vyxeos® With Clofarabine for Pediatric AML
I 期招募中奥地利丹麦德国意大利NCT07156435Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
II 期招募中美国NCT03629171Phase IB/II of CPX-351 for Relapse Prevention in AML
I 期 / II 期招募中美国NCT04990102A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
III 期招募中美国澳大利亚加拿大Puerto RicoNCT04293562CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
I 期招募中美国NCT03896269Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
I 期 / II 期招募中美国NCT04049539Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
I 期招募中美国NCT03826992CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
II 期招募中法国NCT05260528Tazemetostat and Palbociclib With CPX-351for R/R AML
I 期招募中美国NCT05627232Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
I 期 / II 期招募中美国NCT07008638CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
I 期招募中美国NCT05558124
中国患者怎么争取用上这款药
目前境内暂未检索到设点，下面几条途径是更现实的选择，每条都有详细的中文做法。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。